What Is PD-L1 (22C3) Dako CPS IHC Test?

The PD-L1 (22C3) Dako CPS IHC Test is an immunohistochemistry (IHC) diagnostic test used to evaluate the expression of the PD-L1 (Programmed Death-Ligand 1) protein in tumor and immune cells. It is particularly vital in patients diagnosed with:

? Non-Small Cell Lung Cancer (NSCLC)
? Head & Neck Squamous Cell Carcinoma (HNSCC)
?️ Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

This test helps determine the Combined Positive Score (CPS) and guides the use of immune checkpoint inhibitors such as pembrolizumab (Keytruda).

Why Choose PD-L1 (22C3) CPS Test In Dubai?

? FDA-Approved Assay – Validated for multiple cancer types
? Personalized Immunotherapy Guidance – Helps select patients who will benefit from immunotherapy
? Performed On Tumor Tissue Samples – No additional procedure needed
? Widely Available In Dubai’s Leading Cancer Centers
? Accurate IHC By Dako Platform – Trusted globally
? Results Typically In 5–7 Days

Who Should Get This Test?

✔️ Patients Diagnosed With NSCLC, HNSCC, Gastric Or GEJ Cancer
✔️ Individuals Being Considered For PD-1/PD-L1 Inhibitor Therapy
✔️ Cases With Biopsy Or Surgical Tumor Samples Available
✔️ Patients Undergoing Advanced Molecular Tumor Profiling

Benefits Of PD-L1 22C3 CPS IHC Test

✨ Identifies Immunotherapy Candidates For Drugs Like Pembrolizumab
✨ Guides Precision Oncology Treatment Plans
✨ Minimally Invasive – Uses Existing Biopsy/Surgical Specimen
✨ Standardized Scoring Method (CPS)
✨ Globally Recognized Testing Platform (Dako)

Procedure Of The Test

1. Tumor Sample Preparation

   • The test is performed on formalin-fixed, paraffin-embedded (FFPE) tissue obtained during biopsy or surgery.

2. Immunohistochemistry Staining

   • The Dako automated platform uses the 22C3 clone antibody to stain PD-L1 protein in both tumor and immune cells.

3. Scoring (CPS)

   • A pathologist evaluates the stained slide to determine the Combined Positive Score (CPS), which reflects PD-L1 expression.

4. Report Generation

   • Results are reported as CPS <1, 1–19, or ≥20, helping oncologists decide on eligibility for immunotherapy.

Methodology Of The Test

The PD-L1 (22C3) CPS IHC Test is conducted using Immunohistochemistry (IHC) on a Dako Autostainer platform, designed for clinical accuracy and reproducibility.

? PD-L1 Detection

• The 22C3 antibody clone binds specifically to the PD-L1 protein present in tumor and immune cells.

? Combined Positive Score (CPS)

• CPS = (Number of PD-L1 positive tumor cells, lymphocytes, and macrophages ÷ Total viable tumor cells) × 100

? This score helps determine immune response potential and guides treatment with immune checkpoint inhibitors like Keytruda.

Conclusion

The PD-L1 (22C3) Dako CPS IHC Test is a cutting-edge diagnostic tool used in Dubai’s top cancer centers to support personalized immunotherapy decisions. By evaluating PD-L1 expression with a globally trusted scoring method, it helps doctors identify which patients are most likely to benefit from treatments like pembrolizumab.

? With accurate results, minimally invasive processing, and international validation, the PD-L1 22C3 CPS Test is a cornerstone in the future of precision oncology.
? If you’re in Dubai and exploring cancer treatment options, ask your oncologist about this test today. ?️